ClinicalTrials.gg
Not yet recruitingNCT07706166MISP CMVUpdated Sep 29, 2026

Letermovir for R+ Study

A Phase 4 interventional study of Letermovir in Kidney Transplant and Liver Transplant, sponsored by University of Wisconsin, Madison. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Wisconsin, Madison · Phase 4, Interventional, and Prevention

Updated Sep 29, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
146
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV.

Participants will take letermovir for 84 days.

Read the detailed description

This study is being done to see if letermovir prevents CMV reactivation in seropositive participants with a kidney or liver transplant.

02

Conditions studied

  • Kidney Transplant
  • Liver Transplant

Keywords

  • Moderate risk for CMV infection
03

In context

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,189 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
  • Adults who received a kidney transplant, liver transplant, or any combination thereof

Exclusion criteria

Exclusion Criteria:

  • Known to letermovir or its
  • Current participation in another CMV related study
  • Unwilling or unable to participate in the study protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
146 participants (estimated)

Study arms

  • Experimental
    Receive letermovir

    Participants will take letermovir

    Drug: Letermovir

Interventions

  • 1 tablet by mouth, once daily, for 84 days

06

What researchers measure

Primary outcomes

  1. Efficacy of letermovir as a prophylaxis of CMV

    Efficacy will be measured through comparative rates of antiviral failure. Failure will be defined as withdrawal due to intolerance or breakthrough viral replication to a viral load \>1000 IU/mL.

    Time frame: 84 days

Secondary outcomes

  1. Percentage of participants who develop cytomegalovirus-specific cell-mediated immunity

    To be measured using the Eurofins-Viracor CMV inSIGHT™ T Cell Immunity testing. The test measures the strength of T cell responses to Cytomegalovirus (CMV) specific antigens.

    Time frame: 84 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Oct 2026; primary completion for Sep 2029, 35 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 15, 2026
StartEst.
Oct 2026was Sep 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 2026→Oct 2026
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Start date Sep 2026→Oct 2026

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07706166
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Office of Clinical Research Department of Surgery
Contact
surgeryresearch@surgery.wisc.edu
608-576-0788
Margaret R Jorgenson, PharmD
Contact
mjorgenson@uwhealth.org
David Al-Adra, MD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letermovir

Start the discussion